Partner
Mark Bamforth
KAMRA I Investment Comittee Member, Kineticos Disruptor
- Firm
- Kineticos Disruptor
- Title
- KAMRA I Investment Comittee Member
- Role
- Employee
Claim, correct or request removal
Record updated 1 October 2026
About
Mark Bamforth is a General Partner in the Kineticos Anti-Microbial Resistance Accelerator (KAMRA) Fund I. Previously, Mr. Bamforth founded, grew and sold three PE-backed contract development and manufacturing organizations (CDMO); specifically, Arranta Bio, founded in 2019 to focus on the microbiome, which was sold to Recipharm in 2022, Brammer Bio, which was founded in 2015, supporting cell and gene therapies, and was acquired by Thermo Fisher Scientific in 2019, and Gallus Biopharmaceuticals, founded in 2010 to manufacture mAbs, and was sold to Patheon in 2014.
Is this you? Remove my profile
Loading relationship preview